Advertisement

Cytotechnology

, Volume 63, Issue 1, pp 1–5 | Cite as

Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate

  • Vicenta Martínez-SalesEmail author
  • Virtudes Vila
  • Marcos Ferrando
  • Edelmiro Reganon
Brief Report

Abstract

Statins may have beneficial effects in atherogenesis given their antithrombotic properties involving non-lipid mechanisms that modify endothelial function of tissue factor induction by thrombin. In this study, we investigate the effect of atorvastatin on tissue factor (TF) activity in thrombin-stimulated endothelial cells and its regulation through mevalonate or its derivatives. First subculture of human umbilical endothelial cells was used for this study. Cells were treated with thrombin and atorvastatin for different time intervals and dosage. Tissue factor activity was measured as Factor Xa generation induced by Tissue Factor-Factor VIIa complex on confluent cells. Our results show that atorvastatin prevents the thrombin-induced up-regulation of tissue factor activity in a concentration-dependent manner. Mevalonate and geranylgeranyl pyrophosphate reversed this inhibitory effect of atorvastatin on tissue factor activity, while the presence of farnesyl pyrophosphate did not prevent the atorvastatin effect on thrombin-induced tissue factor activity. Rho-kinase inhibitor did not affect the thrombin stimulation of tissue factor activity. High amount of hydrophobic isoprenoid groups decreases the thrombin-induced TF activity and may promote endothelial cell anti-thrombotic action. Rho kinase pathways do not have a major role in the thrombin-mediated TF activity. The inhibitory effect of atorvastatin on thrombin-induced TF activity was partially reversed by MVA and GGPP but not FPP.

Keywords

Atorvastatin Tissue factor Thrombin Endothelial cells Geranylgeranyl pyrophosphate 

Notes

Acknowledgments

The authors thank Guadalupe Manzano and Josefa Llorens for their technical assistance in the performance of the experiments.

References

  1. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992) Post-translational modifications of p21rho proteins. J Biol Chem 267:20033–20038Google Scholar
  2. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL (1996) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60:687–695CrossRefGoogle Scholar
  3. Edwards PA, Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68:157–185CrossRefGoogle Scholar
  4. Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF (2002) Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105:1729–1756CrossRefGoogle Scholar
  5. Ferro D, Basili S, Alessandri C, Cara D, Violi F (2000) Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149:111–116CrossRefGoogle Scholar
  6. Ishibashi T, Sakamoto T, Ohkawara H, Nagata K, Sugimoto K, Sakurada S, Sugimoto N, Watanabe A, Yokoyama K, Sakamoto N, Kurabayashi M, Takuwa Y, Maruyama Y (2003) Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. Ateroscler Thromb Vasc Biol 23:681–687CrossRefGoogle Scholar
  7. Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H (2003) HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 110:227–234CrossRefGoogle Scholar
  8. Li JQ, Zhao SP, Li QZ, Cai YC, Wu LR, Fang Y, Li P (2007) Atorvastatin reduces tissue factor expression in adipose tissue of atherosclerotic rabbits. Int J Cardiol 115:229–234CrossRefGoogle Scholar
  9. Martínez-Sales V, Vila V, Ferrando M, Reganon E (2007) Atorvastatin neutralizes the up-regulation of thrombospondin-1 induced by thrombin in human umbilical vein endothelial cells. Endothelium 14:233–238Google Scholar
  10. Ohkawara H, Ishibashi T, Sakamoto T, Sugimoto K, Nagata K, Yokoyama K, Sakamoto N, Kamioka M, Matsuoka I, Fukuhara S, Sugimoto N, Takuwa Y, Maruyama Y (2005) Thrombin-induced rapid geranyl geranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem 280:10182–10188CrossRefGoogle Scholar
  11. Park HJ, Kong D, Iruela-Arispe ML, Begley U, Tang D, Galper JB (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Cir Res 91:143–150CrossRefGoogle Scholar
  12. Tesfamariam B (2006) The effects of HMG-CoA reductase inhibitors on endothelial cells. Am J Cardiovasc Drugs 6:115–120CrossRefGoogle Scholar
  13. Zhang JJ, Kelm RJ, Biswas P, Kashgarian M, Madri JA (2007) PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. J Cell Physiol 210:527–537CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Vicenta Martínez-Sales
    • 1
    Email author
  • Virtudes Vila
    • 1
  • Marcos Ferrando
    • 2
  • Edelmiro Reganon
    • 1
  1. 1.Centro de InvestigaciónHospital Universitario La Fe AvdaValenciaSpain
  2. 2.Departamento de Obstetricia y GinecologíaHospital Universitario La FeValenciaSpain

Personalised recommendations